Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 114
Filtrar
Más filtros

Bases de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Br J Dermatol ; 180(2): 329-337, 2019 02.
Artículo en Inglés | MEDLINE | ID: mdl-30070708

RESUMEN

BACKGROUND: Patients with psoriasis and clinicians are concerned that infliximab may be associated with a risk of serious infections. OBJECTIVES: To compare the risk of serious infections associated with infliximab in patients with chronic plaque psoriasis against a cohort on nonbiologic systemic therapies. METHODS: A prospective cohort study was performed using data from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Infliximab was compared with nonbiologic systemic therapies, inclusive of any exposure to methotrexate, ciclosporin, acitretin, fumaric acid esters, psoralen-ultraviolet A or hydroxycarbamide. Serious infections were those associated with hospitalization, the use of intravenous antimicrobial therapy and/or those that led to death. Propensity score inverse probability treatment weights were used to adjust for potential confounding from a priori identified covariates. Cox proportional hazards models were calculated to obtain hazard ratios (HRs). RESULTS: In total, 3843 participants were included for analysis up to October 2016. The incidence rates were significantly higher in the infliximab cohort (47·8 per 1000 person-years) [95% confidence interval (CI) 35·7-64·0], compared with 14·2 per 1000 person-years (95% CI 11·5-17·4) in the nonbiologic systemic cohort. Infliximab was associated with an overall increase in the risk of serious infection compared with nonbiologics [adjusted HR (adjHR) 1·95, 95% CI 1·01-3·75] and methotrexate only (adjHR 2·96, 95% CI 1·58-5·57) and a higher risk of serious infection in the first 6 months of therapy (adjHR 3·49, 95% CI 1·14-10·70). CONCLUSIONS: Infliximab is associated with an increased risk of serious infections compared with nonbiologic systemic therapies in patients with psoriasis in the U.K. and the Republic of Ireland.


Asunto(s)
Factores Biológicos/efectos adversos , Fármacos Dermatológicos/efectos adversos , Infecciones/epidemiología , Infliximab/efectos adversos , Psoriasis/tratamiento farmacológico , Adulto , Femenino , Estudios de Seguimiento , Humanos , Incidencia , Infecciones/inducido químicamente , Infecciones/inmunología , Irlanda/epidemiología , Masculino , Metotrexato/efectos adversos , Persona de Mediana Edad , Estudios Prospectivos , Psoriasis/diagnóstico , Psoriasis/inmunología , Sistema de Registros/estadística & datos numéricos , Índice de Severidad de la Enfermedad , Reino Unido/epidemiología
2.
Br J Dermatol ; 179(1): 127-135, 2018 07.
Artículo en Inglés | MEDLINE | ID: mdl-29330859

RESUMEN

BACKGROUND: Psoriasis is a chronic T-cell-mediated skin disease with marked social and economic burdens. Current treatments are unsatisfactory, with unpredictable remission times and incompletely understood modes of action. Recent advances in our understanding of the pathogenesis of psoriasis have identified the imbalance between CD4+ T effector cells, particularly the T helper (Th)17 subset, and regulatory T cells (Tregs) as key to the development of psoriatic lesions, and therefore a novel therapeutic target. OBJECTIVES: To quantify in patients the effects of three commonly used psoriasis treatment modalities on the Th1, Th2, Th17 and Treg subsets, and to test whether any change correlates with clinical response. METHODS: Flow cytometry was used to enumerate Th1, Th2, Th17 and Treg subsets in blood and skin of patients with psoriasis before and after receiving any of the following treatments: narrowband ultraviolet B (NB-UVB), adalimumab and topical betamethasone-calcipotriol combination (Dovobet® ) RESULTS: All patients responded clinically to the treatments. NB-UVB significantly increased the numbers of circulating and skin Tregs, while, by contrast, adalimumab reduced Th17 cells in these compartments, and Dovobet had dual effects by both increasing Tregs and reducing Th17 cells. CONCLUSIONS: The differential effects reported here for the above-mentioned treatment modalities could be exploited to optimize or design therapeutic strategies to overcome the inflammatory drivers more effectively and restore the Th17-Treg balance in psoriasis.


Asunto(s)
Adalimumab/uso terapéutico , Betametasona/análogos & derivados , Calcitriol/análogos & derivados , Fármacos Dermatológicos/uso terapéutico , Psoriasis/tratamiento farmacológico , Linfocitos T Reguladores/efectos de los fármacos , Terapia Ultravioleta , Administración Cutánea , Betametasona/uso terapéutico , Calcitriol/uso terapéutico , Combinación de Medicamentos , Femenino , Humanos , Linfocitosis/inducido químicamente , Linfopenia/inducido químicamente , Masculino , Persona de Mediana Edad , Pomadas , Subgrupos de Linfocitos T , Linfocitos T Reguladores/efectos de la radiación , Células Th17/efectos de los fármacos , Células Th17/efectos de la radiación
3.
Br J Dermatol ; 179(4): 863-871, 2018 10.
Artículo en Inglés | MEDLINE | ID: mdl-29723914

RESUMEN

BACKGROUND: Cancer risk following long-term exposure to systemic immunomodulatory therapies in patients with psoriasis is possible. OBJECTIVES: To assess a dose-response relationship between cumulative length of exposure to biological therapy and risk of cancer. METHODS: Four national studies (a healthcare database from Israel, and prospective cohorts form Italy, Spain and the U.K. and Republic of Ireland) collaborating through Psonet (European Registry of Psoriasis) participated in these nested case-control studies, including nearly 60 000 person-years of observation. 'Cases' were patients who developed an incident cancer. Patients with previous cancers and benign or in situ tumours were excluded. Four cancer-free controls were matched to each case on year of birth, sex, geographic area and registration year. Follow-up for controls was censored at the date of cancer diagnosis for the matched case. Conditional logistic regression was performed by each registry. Results were pooled using random-effects meta-analysis. RESULTS: A total of 728 cases and 2671 controls were identified. After matching, differences between cases and controls were present for the Charlson Comorbidity Index in all three registries, and in the prevalence of previous exposure to psoralen-ultraviolet A and smoking (the British Association of Dermatologists Biologic Interventions Register only). The risk of first cancers was not significantly associated with cumulative exposure to biologics (adjusted odds ratio per year of exposure 1·02, 95% confidence interval 0·92-1·13). Results were similar if squamous and basal cell carcinomas were included in the outcome. CONCLUSIONS: Cumulative length of exposure to biological therapies in patients with psoriasis in real-world clinical practice does not appear to be linked to a higher risk of cancer after several years of use.


Asunto(s)
Productos Biológicos/efectos adversos , Fármacos Dermatológicos/efectos adversos , Factores Inmunológicos/efectos adversos , Neoplasias/epidemiología , Psoriasis/tratamiento farmacológico , Productos Biológicos/administración & dosificación , Fármacos Dermatológicos/administración & dosificación , Relación Dosis-Respuesta a Droga , Europa (Continente)/epidemiología , Humanos , Factores Inmunológicos/administración & dosificación , Incidencia , Israel/epidemiología , Neoplasias/inducido químicamente , Neoplasias/inmunología , Psoriasis/inmunología , Sistema de Registros/estadística & datos numéricos , Factores de Tiempo
4.
Br J Dermatol ; 177(6): 1527-1536, 2017 12.
Artículo en Inglés | MEDLINE | ID: mdl-28391619

RESUMEN

BACKGROUND: Pyoderma gangrenosum (PG) is a painful, ulcerating skin disease with poor evidence for management. Prednisolone and ciclosporin are the most commonly used treatments, although not previously compared within a randomized controlled trial (RCT). OBJECTIVES: To compare the cost-effectiveness of ciclosporin and prednisolone-initiated treatment for patients with PG. METHODS: Quality of life (QoL, EuroQoL five dimensions three level questionnaire, EQ-5D-3L) and resource data were collected as part of the STOP GAP trial: a multicentre, parallel-group, observer-blind RCT. Within-trial analysis used bivariate regression of costs and quality-adjusted life years (QALYs), with multiple imputation of missing data, informing a probabilistic assessment of incremental treatment cost-effectiveness from a health service perspective. RESULTS: In the base case analysis, when compared with prednisolone, ciclosporin was cost-effective due to a reduction in costs [net cost: -£1160; 95% confidence interval (CI) -2991 to 672] and improvement in QoL (net QALYs: 0·055; 95% CI 0·018-0·093). However, this finding appears driven by a minority of patients with large lesions (≥ 20 cm2 ) (net cost: -£5310; 95% CI -9729 to -891; net QALYs: 0·077; 95% CI 0·004-0·151). The incremental cost-effectiveness of ciclosporin for the majority of patients with smaller lesions was £23 374/QALY, although the estimate is imprecise: the probability of being cost-effective at a willingness-to-pay of £20 000/QALY was 43%. CONCLUSIONS: Consistent with the clinical findings of the STOP GAP trial, patients with small lesions should receive treatment guided by the side-effect profiles of the drugs and patient preference - neither strategy is clearly a preferred use of National Health Service resources. However, ciclosporin-initiated treatment may be more cost-effective for patients with large lesions.


Asunto(s)
Ciclosporina/economía , Fármacos Dermatológicos/economía , Prednisolona/economía , Piodermia Gangrenosa/economía , Análisis Costo-Beneficio , Fármacos Dermatológicos/uso terapéutico , Utilización de Instalaciones y Servicios , Recursos en Salud/economía , Recursos en Salud/estadística & datos numéricos , Estado de Salud , Humanos , Prednisolona/uso terapéutico , Piodermia Gangrenosa/tratamiento farmacológico , Años de Vida Ajustados por Calidad de Vida , Método Simple Ciego , Medicina Estatal/economía , Reino Unido
5.
Br J Dermatol ; 177(5): e228-e234, 2017 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-29124728

RESUMEN

Clinical trials may benefit clinical practice in three ways: firstly, clinicians may change their practice according to the new trial evidence; secondly, clinical processes can improve when working on a trial; and thirdly, research capacity is increased. We held a meeting to present and discuss the results of two large multicentre randomized controlled trials delivered through the U.K. Dermatology Clinical Trials Network. Investigators gave reflections on how the trials had changed their clinical practice. The STOP GAP trial showed that prednisolone and ciclosporin are equally effective as first-line systemic treatment for pyoderma gangrenosum. The final decision of which treatment to use should be based on the different adverse event profiles of the two drugs in relation to comorbidities, along with age, disease severity and patient preference. The BLISTER trial showed that starting people with pemphigoid on doxycycline produces acceptable short-term effectiveness and a superior safety profile to oral corticosteroids. Recruiting to these trials has led to the development of new specialist clinics with improved documentation. It has increased the profile of participating departments and embedded research in the department's activities. Helping to design and run these trials has also allowed trial staff to develop new skills in research design, which has been beneficial for career development. These and other benefits of recruiting to the trials are summarized here. We hope that these reflections will inspire wider involvement in clinical research.


Asunto(s)
Estudios Multicéntricos como Asunto , Ensayos Clínicos Controlados Aleatorios como Asunto , Corticoesteroides/uso terapéutico , Actitud del Personal de Salud , Ciclosporina/uso terapéutico , Dermatólogos/psicología , Dermatólogos/estadística & datos numéricos , Doxiciclina/uso terapéutico , Medicina Basada en la Evidencia , Humanos , Penfigoide Ampolloso/tratamiento farmacológico , Pautas de la Práctica en Medicina/estadística & datos numéricos , Prednisolona/uso terapéutico , Piodermia Gangrenosa/tratamiento farmacológico , Investigadores/psicología , Investigadores/estadística & datos numéricos
7.
Br J Dermatol ; 174(5): 970-8, 2016 May.
Artículo en Inglés | MEDLINE | ID: mdl-26801356

RESUMEN

More than 50 interventions have been used to treat hidradenitis suppurativa (HS), and so therapy decisions can be challenging. Our objective was to summarize and appraise randomized controlled trial (RCT) evidence for HS interventions in adults. Searches were conducted in Medline, Embase, CENTRAL, LILACS, five trials registers and abstracts from eight dermatology conferences until 13 August 2015. Two review authors independently assessed study eligibility, extracted data and assessed methodological quality. Primary outcomes were quality of life and adverse effects of the interventions. Twelve trials, from 1983 to 2015, investigating 15 different interventions met our inclusion criteria. The median trial duration was 16 weeks and the median number of participants was 27. Adalimumab 40 mg weekly improved the Dermatology Life Quality Index (DLQI) by 4·0 points, which equates to the minimal clinically important difference for the scale, compared with placebo (95% confidence interval -6·5 to -1·5 points). Evidence quality was reduced to 'moderate' because the results are based on only a single study. Adalimumab 40 mg every other week was ineffective in a meta-analysis of two studies comprising 124 participants. Infliximab 5 mg kg(-1) improved the DLQI score by 8·4 points after 8 weeks in a moderate-quality study completed by 33 of 38 participants. Etanercept 50 mg twice weekly was ineffective. Inclusion of a gentamicin sponge prior to primary closure did not improve outcomes. Other interventions, including topical and oral antibiotics, were investigated by relatively small studies, preventing treatment recommendations due to imprecision. More, larger RCTs are required to investigate most HS interventions, particularly oral treatments and surgical therapy. Moderate-quality evidence suggests that adalimumab given weekly and infliximab are effective, whereas adalimumab every other week is ineffective.


Asunto(s)
Hidradenitis Supurativa/tratamiento farmacológico , Adalimumab/administración & dosificación , Administración Oral , Adulto , Antagonistas de Andrógenos/administración & dosificación , Antibacterianos/administración & dosificación , Clindamicina/administración & dosificación , Acetato de Ciproterona/administración & dosificación , Fármacos Dermatológicos/administración & dosificación , Etanercept/administración & dosificación , Etinilestradiol/administración & dosificación , Gentamicinas/administración & dosificación , Humanos , Infliximab/administración & dosificación , Norgestrel/administración & dosificación , Calidad de Vida , Resultado del Tratamiento , Técnicas de Cierre de Heridas
10.
Clin Exp Immunol ; 180(2): 189-200, 2015 May.
Artículo en Inglés | MEDLINE | ID: mdl-25472480

RESUMEN

Bullous pemphigoid is a blistering skin disease characterized by autoantibodies against the NC16a domain of bullous pemphigoid 180. This study was performed to characterize and map the fine specificity of T cell responses to NC16a. Peripheral blood mononuclear cells (PBMC) from a total of 28 bullous pemphigoid patients and 14 matched controls were tested for proliferative and cytokine responses to recombinant NC16a and a complete panel of 21 overlapping peptides spanning this region of BP180. Proliferative responses to NC16A and the peptide panel in the patients with active disease were similar in frequency and magnitude to those in healthy donors, and included late responses typical of naive cells in approximately 60% of each group. Interleukin (IL)-4 responses were slightly stronger for six peptides, and significantly stronger for Nc16a, in patients than in controls. Factor analysis identified factors that separate responses to the peptide panel discretely into IL-4, T helper type 2 (Th2) pattern, interferon (IFN)-γ, Th1 pattern and IL-10 or transforming growth factor [TGF-ß, regulatory T cell (Treg )] pattern. Factors segregating IL-10 versus IFN-γ were predicted by active blistering or remission, and TGF-ß or IL-10 versus IFN-γ by age. Finally, we confirmed a significant up-regulation of IgE responses to BP180 in the patients with pemphigoid. This shows the complexity of T cell phenotype and fine autoreactive specificity in responses to NC16A, in patients and in normal controls. Important disease-associated factors determine the balance of cytokine responses. Of these, specific IL-4 and IgE responses show the strongest associations with pemphigoid, pointing to an important contribution by Th2 cytokines to pathogenesis.


Asunto(s)
Envejecimiento/inmunología , Autoantígenos/inmunología , Epítopos de Linfocito T/inmunología , Inmunoglobulina E/inmunología , Penfigoide Ampolloso/inmunología , Células Th2/inmunología , Anciano , Anciano de 80 o más Años , Envejecimiento/sangre , Envejecimiento/patología , Autoantígenos/sangre , Citocinas/sangre , Citocinas/inmunología , Epítopos de Linfocito T/sangre , Femenino , Humanos , Inmunoglobulina E/sangre , Masculino , Persona de Mediana Edad , Penfigoide Ampolloso/sangre , Penfigoide Ampolloso/patología , Células Th2/metabolismo , Células Th2/patología
12.
Br J Dermatol ; 173(2): 510-8, 2015 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-25989336

RESUMEN

BACKGROUND: The British Association of Dermatologists Biologic Interventions Register (BADBIR) is a prospective, observational cohort designed to assess the long-term safety of biologic and conventional systemic therapies used for adults with moderate-to-severe psoriasis in the U.K. and Republic of Ireland. OBJECTIVES: To describe the demographics, disease severity and comorbidities of patients with psoriasis on enrolment into BADBIR, and to highlight differences in those commencing biologics compared with those on conventional systemic therapies. METHODS: Baseline data were collected from 151 dermatology departments in the U.K. and Republic of Ireland. Descriptive analysis was conducted. RESULTS: As of August 2014, 8399 patients were registered with BADBIR; 5065 (60%) received biologics, of whom 52·8% received adalimumab, 24·6% etanercept, 18·7% ustekinumab and 3·9% infliximab. In the comparator cohort 44·1% received methotrexate, 23·1% ciclosporin, 18·0% acitretin and 7·6% fumaric acid esters. Overall 4897 (58%) were male. Patients on biologics had a higher mean ± SD age and disease duration than patients on conventional systemic therapies (46·3 ± 12·7 vs. 44·3 ± 14·3 years and 23·0 ± 12·6 vs. 19·0 ± 13·4 years, respectively; both P < 0·001). Mean body mass index, Psoriasis Area and Severity Index and Dermatology Life Quality Index scores for patients on biologics were higher than for those on conventional systemic therapies (31·0 ± 7·2 vs. 30·1 ± 7·3 kg m(-2) ; 16·4 ± 8·3 vs. 15·5 ± 7·9 and 17·4 ± 7·5 vs. 15·0 ± 7·1, respectively; all P < 0·001). In total 71% of all patients had comorbidities and 47% had more than one comorbidity. The most frequent comorbidities were obesity (42·1%), hypertension (25·7%), depression (22·1%) and psoriatic arthritis (17·1%). CONCLUSIONS: BADBIR is an invaluable resource to study the safety and effectiveness of both biologic and conventional systemic therapies. Understanding differences in baseline characteristics between cohorts is crucial in undertaking future pharmacovigilance studies.


Asunto(s)
Psoriasis/epidemiología , Adolescente , Adulto , Edad de Inicio , Anciano , Factores Biológicos/uso terapéutico , Comorbilidad , Fármacos Dermatológicos/uso terapéutico , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Psoriasis/complicaciones , Psoriasis/tratamiento farmacológico , Calidad de Vida , Sistema de Registros , Reino Unido/epidemiología , Adulto Joven
13.
Br J Dermatol ; 180(1): 11, 2019 01.
Artículo en Inglés | MEDLINE | ID: mdl-30604544
14.
Br J Dermatol ; 171(2): 292-7, 2014 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-24702129

RESUMEN

BACKGROUND: The oxidized forms of the fragrance terpenes limonene and linalool are known to cause allergic contact dermatitis. Significant rates of contact allergy to these fragrances have been reported in European studies and in a recent worldwide study. Patch testing to oxidized terpenes is not routinely carried out either in the U.K. or in other centres internationally. OBJECTIVES: To investigate the prevalence of contact allergy to oxidized limonene and linalool in the U.K. METHODS: Between 1 August 2011 and 31 December 2012, 4731 consecutive patients in 13 U.K. dermatology departments were tested for hydroperoxides of limonene 0·3% pet., hydroperoxides of linalool 1·0% pet., stabilized limonene 10·0% pet. and stabilized linalool 10·0% pet. Doubtful (?+) and equivocal (±) reactions were grouped together as irritant reactions. RESULTS: Two hundred and thirty-seven patients (5·0%) had a positive patch test reaction to hydroperoxides of limonene 0·3% pet. and 281 (5·9%) to hydroperoxides of linalool 1·0% pet. Irritant reactions to one or both oxidized terpenes were found in 242 patients (7·3%). Eleven patients (0·2%) had a positive patch test reaction to the stabilized terpenes alone. CONCLUSIONS: This large, multicentre U.K. audit shows a significant rate of allergy to the hydroperoxides of limonene and linalool plus a high rate of irritant reactions. Testing to the oxidized forms alone captures the majority (97·0%; 411 of 422) of positive reactions; testing to nonoxidized terpenes appears to be less useful. We recommend that the hydroperoxides of limonene and linalool be added to an extended baseline patch test series.


Asunto(s)
Ciclohexenos/toxicidad , Dermatitis Alérgica por Contacto/epidemiología , Monoterpenos/toxicidad , Terpenos/toxicidad , Monoterpenos Acíclicos , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Alérgenos/toxicidad , Niño , Preescolar , Femenino , Humanos , Irritantes/toxicidad , Limoneno , Masculino , Persona de Mediana Edad , Pruebas del Parche , Perfumes/toxicidad , Reino Unido/epidemiología , Adulto Joven
15.
Clin Exp Immunol ; 173(1): 38-46, 2013 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-23607572

RESUMEN

Recent evidence points to the T helper type 17 (Th17) subset as key in the pathogenesis of psoriasis, but cells of this type in lesions remain to be fully characterized. Here we isolated, enumerated, functionally tested and clonotyped the CD4(+) Th cell population ex vivo from lesional biopsies and paired peripheral blood samples from psoriasis patients. Th17 cells were over-represented dramatically in lesions from all patients, representing 49-93% of CD4(+) Th cells compared with 3-18% in blood. Most lesional Th17 cells produced interleukin (IL)-17A ex vivo without further stimulation and expressed the CD45RO(+) phenotype characteristic of activated or memory cells. There was no increase in 'natural' [CD25(hi) forkhead box protein 3 (FoxP3(+))] regulatory T cells in lesions versus peripheral blood, but there was enrichment of 'induced' IL-10(+) regulatory T cell numbers in biopsies from some patients. The lesional Th17 cells exhibited a bias in T cell receptor Vß chain usage, suggestive of specific expansion by antigen. The therapeutic challenge is to overcome the dominance of overwhelming numbers of such antigen-specific Th17 cells in psoriatic lesions.


Asunto(s)
Linfocitos T CD4-Positivos/inmunología , Psoriasis/inmunología , Subgrupos de Linfocitos T/inmunología , Células Th17/inmunología , Adulto , Anciano , Biopsia , Sangre/inmunología , Células Clonales/inmunología , Femenino , Reordenamiento Génico de la Cadena beta de los Receptores de Antígenos de los Linfocitos T , Humanos , Memoria Inmunológica , Interleucina-17/metabolismo , Antígenos Comunes de Leucocito/análisis , Activación de Linfocitos , Recuento de Linfocitos , Masculino , Persona de Mediana Edad , Especificidad de Órganos , Psoriasis/sangre , Psoriasis/patología , Piel/inmunología , Piel/patología , Especificidad del Receptor de Antígeno de Linfocitos T , Células Th17/metabolismo , Adulto Joven
18.
Br J Dermatol ; 166(3): 545-54, 2012 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-22356636

RESUMEN

BACKGROUND: The British Association of Dermatologists (BAD) established a web-based pharmacovigilance register to assess the long-term safety of biologics prescribed for patients with severe psoriasis in September 2007. The BAD Biologic Interventions Register (BADBIR) also participates in the network of European psoriasis biologics registers (Psonet). OBJECTIVES: This prospective observational cohort study compares adult patients with psoriasis treated with biologics vs. a comparator group exposed to conventional systemic therapies. METHODS: Following baseline data acquisition, clinicians record changes in therapy, disease activity and adverse events for 5years (6-monthly for 3years, then annually thereafter). Patient details are flagged lifelong on the National Health Service Information Centre system to capture occurrence of malignancy or death. Primary study endpoints include malignancy, infection, serious adverse events and death. Collection of long-term effectiveness data is a subsidiary aim. RESULTS: By November 2011, the number of dermatology centres actively recruiting across the U.K. and Republic of Ireland had risen to 108 and a further 37 were actively engaged in the set-up process. Of the 3176 patients enrolled in the study to date, 2193 were registered within the biologic cohort and 983 in the conventional systemic (nonbiologic-exposed) cohort. CONCLUSIONS: A robust, high-quality, web-based register of biologic and conventional therapy for psoriasis has been established in the U.K. This is the largest project undertaken by the BAD. The data it will provide over the coming years will be invaluable to the safe use of biologics in clinical practice. A U.K.-wide dermatology clinical research network has been established that provides a framework for future studies in other diseases.


Asunto(s)
Productos Biológicos/efectos adversos , Fármacos Dermatológicos/efectos adversos , Farmacovigilancia , Psoriasis/tratamiento farmacológico , Sistema de Registros , Sistemas de Registro de Reacción Adversa a Medicamentos , Recolección de Datos , Dermatología , Humanos , Irlanda , Objetivos Organizacionales , Seguridad del Paciente , Selección de Paciente , Factores de Riesgo , Sociedades Médicas , Reino Unido
19.
Dermatology ; 224(3): 236-43, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22678413

RESUMEN

BACKGROUND: Large disease registries are the preferred method to assess long-term treatment safety. If psoriasis registries collaborate in a network, their power to assess safety is increased. OBJECTIVE: To identify heterogeneity in psoriasis registries and methodological challenges for synthesising the data they provide. METHODS: We surveyed the registries in PSONET and identified and addressed the challenges to collaborative analysis for the network in several round table meetings. RESULTS: Eight out of 10 registries had a prospective comparator cohort with similar disease characteristics but not on biologics. Registries differed in the coding and validation or follow-up of adverse events and in the way they sampled their population. Fifteen challenges to registries collaborating were identified in the areas of operational governance, structural conduct, bias and analysis. CONCLUSIONS: Participation in PSONET, a network of psoriasis registries, helps identify and solve common issues, enhancing the individual registries, and provides larger sets of more powerful safety data in a diverse population. Challenges to interpreting data collectively include heterogeneity in sampling, variable penetration of biologics and compatibility of different datasets.


Asunto(s)
Psoriasis/epidemiología , Sistema de Registros/normas , Adulto , Productos Biológicos/uso terapéutico , Fármacos Dermatológicos/uso terapéutico , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Psoriasis/diagnóstico , Psoriasis/tratamiento farmacológico , Sistema de Registros/estadística & datos numéricos , Índice de Severidad de la Enfermedad , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA